Literature DB >> 25266069

Alanine transferase: An independent indicator of adiposity related comorbidity risk in youth.

Michelle Klein1, Loretta Iazzettii1, Phyllis Speiser2, Dennis Carey2, Steven Shelov3, Siham Accacha4, Ilene Fennoy5, Michael Rosenbaum5, Robert Rapaport1.   

Abstract

BACKGROUND: Elevated levels of alanine aminotransferase (ALT) are associated with obesity and are often a consequence of non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to assess the relationship between ALT and risk factors for adiposity-related co-morbidities in a diverse population of middle school children.
METHODS: We measured height, weight, body fatness (bioelectrical impedance), waist circumference, insulin sensitivity, phase 1 insulin release (acute insulin response following intravenous glucose), beta-cell function (acute insulin response corrected for insulin sensitivity), ALT, lipid profiles, and circulating concentrations of interleukin-6 (IL-6), C-reactive protein, adiponectin, and tumor necrosis factor-α (TNF-α) in a multi-ethnic/racial population of 106 middle school students (aged 11-14 years, 45 female) of varying body mass indexes (BMI).
RESULTS: Alanine aminotransferase was significantly correlated with BMI, % body fat, fat mass, waist circumference, fasting insulin, insulin resistance, triglycerides, and was inversely correlated with high-density lipoprotein cholesterol in children, even though all values of ALT were "normal" (range of 4.0-33.0 U/L). ALT was significantly higher in males than females even when corrected for body fatness. Significant correlations with lipids and insulin resistance persisted even when adjusted for age, gender, and body fatness.
CONCLUSION: Even within the normative range, ALT levels were significantly correlated with anthropomorphic and biochemical risk factors for adiposity-related co-morbidities in youth. Therefore, because ALT is correlated with dyslipidemia, insulin resistance, and central fat distribution, it might also serve as a marker of risk for adiposity-related co-morbidities beyond NAFLD.
© 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  adiposity; alanine transferase; cardiovascular disease; diabetes mellitus in youth; obesity; 关键词:zzm321990肥胖,丙氨酸转移酶,心血管疾病,年轻人糖尿病,肥胖

Mesh:

Substances:

Year:  2014        PMID: 25266069     DOI: 10.1111/1753-0407.12221

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  5 in total

1.  Associations of Early to Mid-Childhood Adiposity with Elevated Mid-Childhood Alanine Aminotransferase Levels in the Project Viva Cohort.

Authors:  Jennifer A Woo Baidal; Erin E Elbel; Joel E Lavine; Sheryl L Rifas-Shiman; Matthew W Gillman; Emily Oken; Elsie M Taveras
Journal:  J Pediatr       Date:  2018-04-04       Impact factor: 4.406

Review 2.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

3.  Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy.

Authors:  Jose Luis Martin-Rodriguez; Jorge Gonzalez-Cantero; Alvaro Gonzalez-Cantero; Juan Pedro Arrebola; Jorge Luis Gonzalez-Calvin
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  Serum alanine aminotransferase activity and risk factors for cardiovascular disease in a Caucasian population: the Tromsø study.

Authors:  Svein Ivar Bekkelund
Journal:  BMC Cardiovasc Disord       Date:  2021-01-13       Impact factor: 2.298

5.  Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort.

Authors:  Julia Kälsch; Lars P Bechmann; Dominik Heider; Jan Best; Paul Manka; Hagen Kälsch; Jan-Peter Sowa; Susanne Moebus; Uta Slomiany; Karl-Heinz Jöckel; Raimund Erbel; Guido Gerken; Ali Canbay
Journal:  Sci Rep       Date:  2015-08-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.